All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
Introducing
Now you can personalise
your Multiple Myeloma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. Digital educational resources delivered on the Multiple Myeloma Hub are supported by an educational grant from Janssen Biotech, Inc. View funders.
Bookmark this article
The Multiple Myeloma Hub was pleased to speak with steering committee member, Bruno Paiva, University of Navarra, Pamplona, ES. We asked, What is the definition and clinical significance of the monoclonal gammopathy of undetermined significance (MGUS)–like phenotype in patients with monoclonal gammopathies?
Definition and clinical significance of the MGUS-like phenotype in monoclonal gammopathies
In this presentation, Paiva summarizes a recent publication1 and discusses the current lack of standardized methods to identify the subgroup of patients with multiple myeloma and light-chain (AL) amyloidosis who have MGUS-like phenotype. He goes on to outline the flow cytometry-based tool that was developed to address this issue and provides the key data it produced with a focus on progression-free and overall survival outcomes. Paiva concludes with the clinical applications of this tool and discusses how these data can help subdivide groups of patients to inform a more individualized treatment approach.
Your opinion matters
Subscribe to get the best content related to multiple myeloma delivered to your inbox